GLP-1 Receptor Agonists in Type 1 Diabetes: What Research Shows So Far

Type 1 diabetes requires lifelong insulin therapy—there is no way around that fundamental need. Yet research shows that insulin alone often falls short. Most people with type 1 diabetes do not achieve their target blood sugar levels using insulin therapy by itself, leaving room for additional treatment strategies that could help close this gap.

This ongoing challenge has sparked interest in adjunctive therapies—medications that work alongside insulin rather than replacing it. One class of drugs gaining attention is the weekly glucagon-like peptide-1 receptor agonists (GLP-1 RA), which are already proven tools in type 2 diabetes and weight management.

Glucagon-like peptide-1 receptor agonists mimic a natural hormone in the body called GLP-1. These medications are FDA-approved for type 2 diabetes, where they help lower blood sugar and support weight loss. The weekly versions require just one injection per week, making them convenient compared to daily medications.

Beyond their blood sugar effects, GLP-1 agonists are also approved to treat obesity. This dual benefit is particularly relevant for people with type 1 diabetes, where weight gain has become an increasingly common concern.

While GLP-1 agonists work well in type 2 diabetes, type 1 diabetes is fundamentally different. Type 1 is an autoimmune condition where the body does not produce insulin. The question researchers are asking is whether GLP-1 medications can help people with type 1 diabetes manage their condition better when used together with insulin.

Two factors make this research especially important. First, many people with type 1 diabetes struggle to reach their blood sugar goals despite their best insulin management efforts. Second, obesity is increasingly affecting the type 1 diabetes population, and GLP-1 medications have shown effectiveness in addressing weight concerns in other groups.

Despite growing interest, significant knowledge gaps remain about using weekly GLP-1 medications in type 1 diabetes. Researchers have outlined key questions that need answers: How safe and effective are these medications when combined with insulin? What doses work best? Which people with type 1 diabetes would benefit most? How do these medications interact with different insulin regimens?

To close these gaps, additional clinical trials are being planned and developed. These studies will help establish whether weekly GLP-1 agonists belong in the type 1 diabetes treatment toolkit and, if so, how best to use them.

The study of weekly GLP-1 receptor agonists in type 1 diabetes represents an evolving area of research. While these medications show promise as a potential adjunctive therapy, it is important to remember that they are not a replacement for insulin and research in this population is still developing.

People with type 1 diabetes interested in learning about new treatment options should continue working with their diabetes care team. Upcoming clinical trials may offer opportunities to participate in this research and contribute to our understanding of how these medications might help people with type 1 diabetes achieve better health outcomes.

Source: Endocrinology and metabolism clinics of North America. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.